- Trial Phase
- Approved
- Time to Market
- Already marketed since 2014. The next lifecycle milestone is the Otezla XR extended-release formulation, which was approved in August 2025.
- Why 3/10
- Otezla is an approved, marketed drug with no pending PDUFA date, pivotal readout, or regulatory decision. The next hard catalyst is the February 2028 patent expiration allowing generic entry, which is over 12 months away and a known, gradual event rather than a binary catalyst. Otezla also represents only about 4.6% of Amgen's total revenue, making it a modest contributor within a diversified portfolio.
No near-term binary catalyst exists for Otezla. The next major event is the February 2028 patent cliff when generic apremilast can enter the US market, which is well-telegraphed and roughly 15 months away. Watch quarterly sales trends for the pace of erosion and any Otezla XR extended-release uptake as a lifecycle management signal. For Amgen investors, Otezla's decline is one of many moving parts in a $39B+ revenue portfolio dominated by newer growth drivers like Repatha, Tezspire, and Imdelltra.
Price Chart
Executive Summary
Otezla (apremilast) is an oral PDE4 inhibitor approved for psoriatic arthritis, plaque psoriasis, and Behcet's disease oral ulcers in both adults and children. Amgen acquired the drug for $13.4B in 2019 as part of a regulatory divestiture. Otezla generated about $2.3B in 2025 sales (up 7% YoY), but Q3 2026 sales fell 18% YoY to $481M, pressured by lower volume and pricing. A Federal Circuit ruling blocks US generic entry until February 2028, after which multiple generic manufacturers are expected to launch. Otezla is a mature, declining product representing roughly 4.6% of Amgen's total quarterly revenue, within a highly diversified portfolio.
How It Works
Otezla is a pill (not an injection or infusion) that works inside immune cells to reduce inflammation. It blocks an enzyme called PDE4, which helps lower levels of inflammatory chemicals that drive psoriasis, psoriatic arthritis, and Behcet's disease mouth ulcers. Unlike biologic drugs that target specific immune proteins, Otezla modulates inflammation more broadly at the cellular level.
Trial Status
Otezla was first FDA-approved in 2014. Since then, Amgen has secured label expansions for pediatric plaque psoriasis (2024, based on the Phase 3 SPROUT trial) and pediatric psoriatic arthritis (July 2025). The Otezla XR extended-release formulation was approved in August 2025. No new pivotal trials are ongoing for Otezla; recent Phase 3 trials involving apremilast have been as an active comparator for competitor drugs (e.g., Alumis' ESK-001 in plaque psoriasis).
The Two-Sided Case
Upcoming Catalysts
- February 2028: US patent expiration allowing generic apremilast entry (blocked by court injunction until this date)
- Quarterly sales reports: tracking the pace of revenue erosion as the patent cliff approaches
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report